Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $616

Benzinga Newsdesk www.benzinga.com Positive 82.8%

Neg 0% Neu 0% Pos 82.8%

Morgan Stanley analyst Terence Flynn maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $612 to $616.